These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

369 related items for PubMed ID: 29308589

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin.
    Cicero TJ, Ellis MS.
    JAMA Psychiatry; 2015 May; 72(5):424-30. PubMed ID: 25760692
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation.
    Cassidy TA, DasMahapatra P, Black RA, Wieman MS, Butler SF.
    Pain Med; 2014 Mar; 15(3):440-51. PubMed ID: 24330279
    [Abstract] [Full Text] [Related]

  • 6. Changes in drug use patterns reported on the web after the introduction of ADF OxyContin: findings from the Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS) System Web Monitoring Program.
    Vosburg SK, Haynes C, Besharat A, Green JL.
    Pharmacoepidemiol Drug Saf; 2017 Sep; 26(9):1044-1052. PubMed ID: 28653782
    [Abstract] [Full Text] [Related]

  • 7. Decreased diversion by doctor-shopping for a reformulated extended release oxycodone product (OxyContin).
    Chilcoat HD, Coplan PM, Harikrishnan V, Alexander L.
    Drug Alcohol Depend; 2016 Aug 01; 165():221-8. PubMed ID: 27372220
    [Abstract] [Full Text] [Related]

  • 8. Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone.
    Severtson SG, Ellis MS, Kurtz SP, Rosenblum A, Cicero TJ, Parrino MW, Gilbert MK, Buttram ME, Dasgupta N, BucherBartelson B, Green JL, Dart RC.
    Drug Alcohol Depend; 2016 Nov 01; 168():219-229. PubMed ID: 27716575
    [Abstract] [Full Text] [Related]

  • 9. Monitoring of internet forums to evaluate reactions to the introduction of reformulated OxyContin to deter abuse.
    McNaughton EC, Coplan PM, Black RA, Weber SE, Chilcoat HD, Butler SF.
    J Med Internet Res; 2014 May 02; 16(5):e119. PubMed ID: 24800858
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS).
    Cicero TJ, Dart RC, Inciardi JA, Woody GE, Schnoll S, Muñoz A.
    Pain Med; 2007 Mar 02; 8(2):157-70. PubMed ID: 17305687
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Opioid use following the introduction of an extended-release oxycodone formulation with tamper-resistant properties: Prospective historical chart review in methadone-maintained patients.
    Sankey C, Setnik B, Harsanyi Z, Michalko K, Yang Z, Geoffroy P.
    J Opioid Manag; 2016 Mar 02; 12(2):149-59. PubMed ID: 27194200
    [Abstract] [Full Text] [Related]

  • 14. Impact of abuse-deterrent OxyContin on prescription opioid utilization.
    Hwang CS, Chang HY, Alexander GC.
    Pharmacoepidemiol Drug Saf; 2015 Feb 02; 24(2):197-204. PubMed ID: 25393216
    [Abstract] [Full Text] [Related]

  • 15. Patterns of abuse and routes of administration for immediate-release hydrocodone combination products.
    Cassidy TA, Oyedele N, Mickle TC, Guenther S, Budman SH.
    Pharmacoepidemiol Drug Saf; 2017 Sep 02; 26(9):1071-1082. PubMed ID: 28771942
    [Abstract] [Full Text] [Related]

  • 16. Evaluating the effectiveness of reformulated extended-release oxycodone with abuse-deterrent properties on reducing non-oral abuse among individuals assessed for substance abuse treatment with the Addiction Severity Index-Multimedia Version (ASI-MV).
    Rodriguez RD, Dailey Govoni T, Rajagopal V, Green JL.
    Curr Med Res Opin; 2023 Apr 02; 39(4):579-587. PubMed ID: 36762423
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Protocol: changes in rates of opioid overdose and poisoning events in an integrated health system following the introduction of a formulation of OxyContin® with abuse-deterrent properties.
    Janoff SL, Perrin NA, Coplan PM, Chilcoat HD, Campbell CI, Green CA.
    BMC Pharmacol Toxicol; 2016 May 14; 17(1):21. PubMed ID: 27177423
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Use of prescription opioids with abuse-deterrent technology to address opioid abuse.
    Michna E, Kirson NY, Shei A, Birnbaum HG, Ben-Joseph R.
    Curr Med Res Opin; 2014 Aug 14; 30(8):1589-98. PubMed ID: 24738694
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.